TOP TEN perturbations for NM_000303 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000303
Selected probe(set): 203201_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000303 (203201_at) across 5339 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.912981
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

plicamycin study 1 (100 nM) / vehicle (PBS) treated TC-32 cell sample

Relative Expression (log2-ratio):-2.3729572
Number of Samples:3 / 3
Experimental plicamycin study 1 (100 nM)
TC-32 Ewing?s sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code:
Control vehicle (PBS) treated TC-32 cell sample
TC-32 Ewing?s sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours.

prostate cancer study 8 (ptasc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):2.233077
Number of Samples:2 / 5
Experimental prostate cancer study 8 (ptasc)
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.1353788
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ? 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):1.9450006
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))

Relative Expression (log2-ratio):1.8542328
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---

R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-1.8263016
Number of Samples:4 / 4
Experimental R547 study 3 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 ?mol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

plicamycin study 2 (100 nM) / vehicle (PBS) treated TC-71 cell sample

Relative Expression (log2-ratio):-1.7819557
Number of Samples:3 / 3
Experimental plicamycin study 2 (100 nM)
TC-71 Ewing?s sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code:
Control vehicle (PBS) treated TC-71 cell sample
TC-71 Ewing?s sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours.

prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):1.7367573
Number of Samples:3 / 5
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

R547 study 4 (4h) / vehicle (DMSO) treated HCT116 cell sample

Relative Expression (log2-ratio):-1.7358027
Number of Samples:3 / 4
Experimental R547 study 4 (4h)
Human colon carcinoma cell line HCT116 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 4 hours at a 3xIC90 concentration of 0.6 ?mol/L. ATC code:---
Control vehicle (DMSO) treated HCT116 cell sample
Human colon carcinoma cell line HCT116 treated with vehicle (DMSO) for 4 hours.